0599866 - ÚOCHB 2025 RIV CZ eng A - Abstrakt
Petrová, Magdalena - Pohl, Radek - Pachl, Petr - Dávidová, Eva - Viktorová, J. - Bogdanová, K. - Večeřová, R. - Kolář, M. - Rejman, Dominik
Nucleoside boronic acids.
Czech Chemical Society Symposium Series. Roč. 22, č. 6 (2024), s. 201, č. článku L-01. ISSN 2336-7202.
[Annual meeting of the National Institute of Virology and Bacteriology (NIVB) /3./. 30.09.2024-02.10.2024, Kutná Hora]
Grant CEP: GA MŠMT(CZ) LX22NPO5103
Institucionální podpora: RVO:61388963
Klíčová slova: boronic acids * inhibitors * bacteria resistance
Obor OECD: Microbiology
Web výsledku:
http://www.ccsss.cz/index.php/ccsss/issue/view/48/87

Advances in the field of boron chemistry have allowed this element to be used in a range of new materials, including applications for medicine. Boron-based drugs have now been developed as therapeutic agents for cancer, and for viral, bacterial, and fungal infections. Bortezomib (Velcade®) was the first boronic acid-containing drug approved in 2003 as aproteasome inhibitor for the treatment of multiple myeloma. Several other boron-based compounds are in clinical trials, illustrating the promise of this class of chemical in drug discovery. The boronic acid group is capable of forming bonds that are substantially stronger than a typical hydrogen bond (~75 vs.~20–30 kJ/mol). The boronate group has previously been shown to bind in a mode where it ca associate with multiple amino acids all at the one time (e.g. penicillin-binding protein).
Trvalý link: https://hdl.handle.net/11104/0357290